Literature DB >> 19896457

Cofilin phosphorylation is involved in nitric oxide/cGMP-mediated nociception.

Lars Zulauf1, Ovidiu Coste, Claudiu Marian, Christine Möser, Christian Brenneis, Ellen Niederberger.   

Abstract

There is convincing evidence that nitric oxide (NO), cGMP and cGMP-dependent protein kinase I (PKG-I) are involved in the development of hyperalgesia in response to noxious stimuli. However, downstream target proteins contributing to nociception have not been completely identified so far. Several reports indicate a role of the NO/cGMP/PKG cascade in the regulation of neurite outgrowth which is suggested to be involved in specific mechanisms of nociception. Since neurite outgrowth is strongly dependent on modulation of cytoskeleton proteins we were interested in the impact of PKG-I activation on the actin cytoskeleton and its role in inflammatory hyperalgesia. Therefore we investigated the actin-destabilising protein cofilin and its NO-dependent effects in vitro in primary neuronal cultures as well as in vivo in the zymosan-induced paw inflammation model in rats. In primary neurons from rats, treatment with the PKG-I activator 8-Br-cGMP induced a time-dependent phosphorylation of cofilin and significantly increased neurite outgrowth. Further functional analysis revealed that the underlying signal transduction pathways involve activation of the Rho-GTPases RhoA, Rac1 and Cdc42 and their corresponding downstream targets Rho-kinase (ROCK) and p21-activated kinase (PAK). In vivo, treatment of rats with the NO-synthase inhibitor l-NAME and the ROCK-inhibitor Y-27632, respectively, led to a significant decrease of cofilin phosphorylation in the spinal cord and resulted in antinociceptive effects in a model of inflammatory hyperalgesia. Our results suggest that cofilin represents a downstream target of NO/cGMP/PKG signal transduction in neurons thus indicating that it is involved in NO-mediated nociception.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19896457     DOI: 10.1016/j.bbrc.2009.10.166

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Regulation of retinoschisin secretion in Weri-Rb1 cells by the F-actin and microtubule cytoskeleton.

Authors:  Eiko Kitamura; Yekaterina E Gribanova; Debora B Farber
Journal:  PLoS One       Date:  2011-06-27       Impact factor: 3.240

2.  LncRNA expression in the spinal cord modulated by minocycline in a mouse model of spared nerve injury.

Authors:  Zihao Liu; Ying Liang; Honghua Wang; Zhenhe Lu; Jinsheng Chen; Qiaodong Huang; Lei Sheng; Yinghong Ma; Huiying Du; Qingjuan Gong
Journal:  J Pain Res       Date:  2017-10-24       Impact factor: 3.133

3.  The small GTPase CDC42 regulates actin dynamics during porcine oocyte maturation.

Authors:  Yu Zhang; Qiao-Chu Wang; Jun Liu; Bo Xiong; Xiang-Shun Cui; Nam-Hyung Kim; Shao-Chen Sun
Journal:  J Reprod Dev       Date:  2017-08-05       Impact factor: 2.214

Review 4.  Neuronal Nitric Oxide Synthase (nNOS) in Neutrophils: An Insight.

Authors:  Rashmi Saini; Zaffar Azam; Leena Sapra; Rupesh K Srivastava
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

5.  Inhibition of the Rho/Rho kinase pathway prevents lipopolysaccharide-induced hyperalgesia and the release of TNF-α and IL-1β in the mouse spinal cord.

Authors:  Cunjin Wang; Siyuan Song; Yang Zhang; Yali Ge; Xiangzhi Fang; Tianfeng Huang; Jin Du; Ju Gao
Journal:  Sci Rep       Date:  2015-09-29       Impact factor: 4.379

6.  Dual effects of Rho-kinase inhibitors on a rat model of inflammatory pain.

Authors:  Patricia Paiva-Lima; Y S Bakhle; Janetti Nogueira Francischi
Journal:  Pain Res Manag       Date:  2014-07-03       Impact factor: 3.037

7.  Phosphodiesterase inhibitors roflumilast and vardenafil prevent sleep deprivation-induced deficits in spatial pattern separation.

Authors:  Pim R A Heckman; Femke Roig Kuhn; Frank Raven; Youri G Bolsius; Jos Prickaerts; Peter Meerlo; Robbert Havekes
Journal:  Synapse       Date:  2020-03-03       Impact factor: 2.537

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.